ConductScience.org, home

Paper8759268

Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid.

Elder MJ and 2 others. Br J Ophthalmol, 1996. Cited by 41 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid. Papers, record 8759268. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8759268

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid.
PubMed
Journal
Br J Ophthalmol
PubMed
Year
1996
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
2.25
iCite
Revised in PubMed
2019-05-01
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Elder MJM J
2Leonard JJ
3Dart JKJ K

Source PubMed

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory AgentsMajor topic
ConjunctivitisMajor topic
Pemphigoid, Benign Mucous MembraneMajor topic
SulfapyridineMajor topic
Administration, Oral
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Prospective Studies

Source PubMed

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15,646,069Erythema elevatum diutinum--vesicular lesions and sulphone response.Br J Dermatol1968https://conductscience.org/library/papers/5646069PubMed
213,845,241Dermatitis herpetiformis with acantholysis or pemphigus with response to sulfonamides: report of two cases.Arch Dermatol1960https://conductscience.org/library/papers/13845241PubMed
35,120,174Benign mucous membrane pemphigoid.Arch Dermatol1971https://conductscience.org/library/papers/5120174PubMed
44,141,602Immunosuppressive and cytotoxic drugs in dermatology.Arch Dermatol1974https://conductscience.org/library/papers/4141602PubMed
5848,360Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases.Acta Med Scand1977https://conductscience.org/library/papers/848360PubMed
6324,403Bullous pemphigoid responding to sulfapyridine and the sulfones.Arch Dermatol1977https://conductscience.org/library/papers/324403PubMed
7868,943Autoimmune phenomena in ocular cicatricial pemphigoid.Am J Ophthalmol1977https://conductscience.org/library/papers/868943PubMed
8334,088Electron microscopic studies in dermatitis herpetiformis in relation to the pattern of immune deposits in the skin.Arch Dermatol Res (1975)1977https://conductscience.org/library/papers/334088PubMed
921,720Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.Br Med J1977https://conductscience.org/library/papers/21720PubMed
10528,697Sulfones and sulfonamides in dermatology today.J Am Acad Dermatol1979https://conductscience.org/library/papers/528697PubMed
11537,759The acute manifestations of ocular cicatricial pemphigoid: diagnosis and treatment.Ophthalmology1979https://conductscience.org/library/papers/537759PubMed
127,015,218Ocular cicatricial pemphigoid.Ophthalmology1981https://conductscience.org/library/papers/7015218PubMed
137,037,880Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.J Am Acad Dermatol1982https://conductscience.org/library/papers/7037880PubMed
147,048,180Immunosuppressive therapy for progressive ocular cicatricial pemphigoid.Ophthalmology1982https://conductscience.org/library/papers/7048180PubMed
156,353,928Immunosuppressive therapy in ocular cicatricial pemphigoid.Am J Ophthalmol1983https://conductscience.org/library/papers/6353928PubMed
166,142,465A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route.Pharmatherapeutica1984https://conductscience.org/library/papers/6142465PubMed
172,860,942Which component of sulphasalazine is active in rheumatoid arthritis?Br Med J (Clin Res Ed)1985https://conductscience.org/library/papers/2860942PubMed
182,861,876Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.Br J Rheumatol1985https://conductscience.org/library/papers/2861876PubMed
192,864,155Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.Clin Pharmacokinet1985https://conductscience.org/library/papers/2864155PubMed
202,866,061Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.Clin Sci (Lond)1985https://conductscience.org/library/papers/2866061PubMed

See all 39 references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
32,313,985Signaling lipids as diagnostic biomarkers for ocular surface cicatrizing conjunctivitis.J Mol Med (Berl)2020https://conductscience.org/library/papers/32313985PubMed
28,106,896The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.Eye (Lond)2017https://conductscience.org/library/papers/28106896PubMed
20,030,429Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.Drugs Aging2010https://conductscience.org/library/papers/20030429PubMed
18,392,628[Mucous membrane pemphigoid with ocular involvement. Part II: therapy].Ophthalmologe2008https://conductscience.org/library/papers/18392628PubMed
18,360,613Therapy of autoimmune bullous diseases.Ther Clin Risk Manag2007https://conductscience.org/library/papers/18360613PubMed
15,967,079Ocular cicatricial pemphigoid: manifestations and management.Curr Allergy Asthma Rep2005https://conductscience.org/library/papers/15967079PubMed
12,831,291Autoimmune bullous dermatoses in the elderly: diagnosis and management.Drugs Aging2003https://conductscience.org/library/papers/12831291PubMed
12,535,507Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita.Cochrane Database Syst Rev2003https://conductscience.org/library/papers/12535507PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8759268

GET https://conductscience.org/api/papers/v1/8759268/references?page=2